Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Gu, Yanyun ^a   Wang, Xiaokai ^b,c   Li, Junhua ^b   Zhang, Yifei ^a   Zhong, Huanzi ^b,d   Liu, Ruixin ^a   Zhang, Dongya ^b   Feng, Qiang ^b   Xie, Xiaoyan ^a   Hong, Jie ^a   Ren, Huahui ^b   Liu, Wei ^e   Ma, Jing ^e   Su, Qing ^f   Zhang, Hongmei ^f   Yang, Jialin ^g   Wang, Xiaoling ^h   Zhao, Xinjie ^h   Gu, Weiqiong ^a   Bi, Yufang ^a   Peng, Yongde ⁱ   Xu, Xiaoqiang ^b,c   Xia, Huihua ^b   Li, Fang ^b   Xu, Xun ^b   Yang, Huanming ^b,j   Xu, Guowang ^h   Madsen, Lise ^b,c,k   Kristiansen, Karsten ^b,d   Ning, Guang ^a   Wang, Weiqing ^a   more..

^a Shanghai Clinical Center for Endocrine and Metabolic Diseases   (China)

^b BGI SHENZHEN   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g The Central Hospital of Minhang District   (China)

^h DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

ⁱ SHANGHAI JIAO TONG UNIVERSITY   (China)

^j James D Watson Institute of Genome Sciences   (China)

^k INSTITUTE OF MARINE RESEARCH   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADIPONECTIN; BILE ACID; BILE ACID CONJUGATE; CHENODEOXYCHOLIC ACID; CHOLESTEROL; CHOLIC ACID; DEOXYCHOLIC ACID; GLIPIZIDE; GLUCOSE; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; GLYCODEOXYCHOLIC ACID; GLYCOLITHOCHOLIC ACID; GLYCOURSODEOXYCHOLIC ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; LITHOCHOLIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAURINE CONJUGATED BILE ACID; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; TAUROLITHOCHOLIC ACID; TAUROURSODEOXYCHOLIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; ANTIDIABETIC AGENT; GLYCOSIDASE INHIBITOR;

ABUNDANCE; ACID; BACTERIUM; DIABETES; METABOLISM; MICROORGANISM;

ACTINOBACTERIA; ADULT; ALISTIPES; ALISTIPES PUTREDINIS; ALISTIPES SHAHII; ANAEROTRUNCUS COLIHOMINIS; ARTICLE; BACTERIAL GENE; BACTERIUM; BACTEROIDES; BACTEROIDES CACCAE; BACTEROIDES CLARUS; BACTEROIDES DOREI; BACTEROIDES FINEGOLDII; BACTEROIDES INTESTINALIS; BACTEROIDES STERCORIS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; BACTEROIDES VULGATUS; BACTEROIDETES; BIFIDOBACTERIUM; BIFIDOBACTERIUM ADOLESCENTIS; BIFIDOBACTERIUM CATENULATUM; BIFIDOBACTERIUM LONGUM; BILE ACID BLOOD LEVEL; BILE ACID METABOLISM; BILOPHILA WADSWORTHIA; CAPNOCYTOPHAGA; CHOLESTEROL BLOOD LEVEL; CLINICAL OUTCOME; CLOSTRIDIUM; CLOSTRIDIUM BOLTEAE; CLOSTRIDIUM LEPTUM; CLOSTRIDIUM SCINDENS; COHORT ANALYSIS; COLLINSELLA AEROFACIENS; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; EGGERTHELLA LENTA; EUBACTERIUM; EUBACTERIUM ELIGENS; EUBACTERIUM SIRAEUM; EUBACTERIUM VENTRIOSUM; FEMALE; FIRMICUTES; FUSOBACTERIUM MORTIFERUM; GLUCOSE BLOOD LEVEL; HOLDEMANIA FILIFORMIS; HUMAN; INSULIN BLOOD LEVEL; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS AMYLOVORUS; LACTOBACILLUS CASEI; LACTOBACILLUS FERMENTUM; LACTOBACILLUS GASSERI; LACTOBACILLUS JOHNSONII; LACTOBACILLUS ORIS; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; MAJOR CLINICAL STUDY; MALE; MEGASPHAERA ELSDENII; METABOLIC PARAMETERS; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ODORIBACTER SPLANCHNICUS; OPEN STUDY; OXALOBACTER FORMIGENES; PARABACTEROIDES DISTASONIS; POPULATION ABUNDANCE; PREVOTELLA; PROTEOBACTERIA; PSEUDOFLAVONIFRACTOR CAPILLOSUS; RANDOMIZED CONTROLLED TRIAL; ROSEBURIA HOMINIS; ROSEBURIA INTESTINALIS; ROSEBURIA INULINIVORANS; RUMINOCOCCUS; RUMINOCOCCUS LACTARIS; RUMINOCOCCUS TORQUES; STREPTOCOCCUS; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS THERMOPHILUS; STREPTOCOCCUS VESTIBULARIS; TREATMENT RESPONSE; BLOOD; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECT; FECES; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; POPULATION DYNAMICS;

BACTEROIDES; BIFIDOBACTERIUM; LACTOBACILLUS; PREVOTELLA;

ACARBOSE; BACTEROIDES; BIFIDOBACTERIUM; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 2; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; GLIPIZIDE; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; LACTOBACILLUS; MALE; MIDDLE AGED; POPULATION DYNAMICS;

EID: 85035341770     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01682-2     Document Type: Article

References (59)

1. Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369-2379 (2016).
2. Shapiro, H., Suez, J. & Elinav, E. Personalized microbiome-based approaches to metabolic syndrome management and prevention. J. Diabetes 9, 226-236 (2017).
3. Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60 (2012).
4. Karlsson, F. H. et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498, 99-103 (2013).
5. Aron-Wisnewsky, J., Dore, J. & Clement, K. The importance of the gut microbiota after bariatric surgery. Nat. Rev. Gastroenterol. Hepatol. 9, 590-598 (2012).
6. Liou, A. P. et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci. Transl. Med. 5, 178ra141 (2013).
7. Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850-858 (2017).
8. Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262-266 (2015).
9. Lien, F. et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J. Clin. Invest. 124, 1037-1051 (2014).
10. Pedersen, H. K. et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535, 376-381 (2016).
11. Liu, R. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat. Med. 23, 859-868 (2017).
12. Wahlstrom, A., Sayin, S. I., Marschall, H. U. & Backhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell. Metab. 24, 41-50 (2016).
13. Ferrannini, E. et al. Increased bile acid synthesis and deconjugation after biliopancreatic diversion. Diabetes 64, 3377-3385 (2015).
14. Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D. & Ferrannini, E. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes 62, 4184-4191 (2013).
15. Wewalka, M., Patti, M. E., Barbato, C., Houten, S. M. & Goldfine, A. B. Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J. Clin. Endocrinol. Metab. 99, 1442-1451 (2014).
16. Ryan, K. K. et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509, 183-188 (2014).
17. Weng, J. et al. Standards of care for type 2 diabetes in China. Diabetes. Metab. Res. Rev. 32, 442-458 (2016).
18. Ko, S. H. et al. 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab. J. 35, 431-436 (2011).
19. Zhang, J. P. et al. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels. J. Diabetes 8, 559-567 (2016).
20. Kahn, S. E., Cooper, M. E. & Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383, 1068-1083 (2014).
21. Lebovitz, H. E. alpha-Glucosidase inhibitors. Endocrinol. Metab. Clin. North Am. 26, 539-551 (1997).
22. American Diabetes Association. Executive summary: standards of medical care in diabetes-2012. Diabetes Care 35, S4-S10 (2012).
23. Xu, Y. et al. Plasma glucose and hemoglobin A1c for the detection of diabetes in Chinese adults. J. Diabetes 8, 378-386 (2016).
24. Deng, Y. et al. Postprandial glucose, insulin and incretin responses to different carbohydrate tolerance tests. J. Diabetes 7, 820-829 (2015).
25. Bedogni, G. et al. The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 33 (2006).
26. Degirolamo, C., Sabbà, C. & Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51-69 (2015).
27. Joyce, S. A., Gahan, C. G. Bile acid modifications at the microbe-host interface: potential for nutraceutical and pharmaceutical interventions in host health. Annu. Rev. Food. Sci. Technol. 7, 313-333 (2016).
28. Li, J. et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 32, 834-841 (2014).
29. Ridlon, J. M., Kang, D. J., Hylemon, P. B. & Bajaj, J S. Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30, 332-338 (2014).
30. Degirolamo, C., Rainaldi, S., Bovenga, F., Murzilli, S. & Moschetta, A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 7, 12-18 (2014).
31. Joyce, S. A. et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc. Natl Acad. Sci. USA 11, 7421-7426 (2014).
32. Ridlon, J. M., Kang, D. J. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241-259 (2006).
33. Tannock, G. W., Dashkevicz, M. P. & Feighner, S. D. Lactobacilli and bile salt hydrolase in the murine intestinal tract. Appl. Environ. Microbiol. 55, 1848-1851 (1989).
34. Takahashi, T. & Morotomi, M. Absence of cholic acid 7 alpha-dehydroxylase activity in the strains of Lactobacillus and Bifidobacterium. J. Dairy Sci. 77, 3275-3286 (1994).
35. Deitch, E. A. The role of intestinal barrier failure and bacterial translocation in the development of systemic infection and multiple organ failure. Arch. Surg. 125, 403-404 (1990).
36. De-Souza, D. A. & Greene, L. J. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit. Care Med. 33, 1125-1135 (2005).
37. Rey, F. E. et al. Metabolic niche of a prominent sulfate-reducing human gut bacterium. Proc. Natl Acad. Sci. USA 110, 13582-13587 (2013).
38. Manichanh, C., Borruel, N., Casellas, F. & Guarner, F. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 599-608 (2012).
39. Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772 (2007).
40. Pussinen, P. J., Havulinna, A. S., Lehto, M., Sundvall, J. & Salomaa, V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 34, 392-397 (2011).
41. Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174-180 (2011).
42. Wu, G. D. et al. Linking long-Term dietary patterns with gut microbial enterotypes. Science 334, 105-108 (2011).
43. Knights, D. et al. Rethinking "enterotypes". Cell Host Microbe. 16, 433-437 (2014).
44. Yang, W. et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: An open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2, 46-55 (2014).
45. Chiasson, J.L. et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359, 2072-2077 (2002).
46. Zhang, Y. et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl Acad. Sci. USA 103, 1006-1011 (2006).
47. Li, T. & Chiang, J. Y. Bile acid signaling in metabolic disease and drug therapy. Pharmacol. Rev. 66, 948-983 (2014).
48. Ma, K., Saha, P. K., Chan, L. & Moore, D. D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116, 1102-1109 (2006).
49. Mingrone, G. et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N. Eng. J. Med. 366, 1577-1585 (2012).
50. Song, K. H., Li, T., Owsley, E., Strom, S. & Chiang, J. Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49, 297-305 (2009).
51. Jiang, C. et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125, 386-402 (2015).
52. Gabir, M. M. et al. The1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23, 1108-1112 (2000).
53. Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079-1084 (2015).
54. Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat. Med. 21, 895-905 (2015).
55. John, C. et al. A liquid chromatography-Tandem mass spectrometry-based method for the simultaneous determination of hydroxy sterols and bile acids. J. Chromatogr. A 1371, 184-195 (2014).
56. Sunagawa, S. et al. Metagenomic species profiling using universal phylogenetic marker genes. Nat. Methods 10, 1196-1199 (2013).
57. Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541-546 (2013).
58. Backhed, F. et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17, 690-703 (2015).
59. Kanehisa, M., Sato, Y. & Morishima, K. BlastKOALA and GhostKOALA: KEGG tools for functional characterization of genome and metagenome sequences. J. Mol. Biol. 428, 726-731 (2016).